Hogan Lovells 2024 Election Impact and Congressional Outlook Report
The delisting tender offer by Novartis, which was offered to all MorphoSys shareholders to acquire their MorphoSys shares against payment of a cash consideration of EUR 68.00 per MorphoSys share, followed the voluntary public takeover offer by Novartis published in April 2024 and settled in May 2024.
MorphoSys is a global biopharmaceutical company, which develops and delivers innovative cancer medicines and brings them to patients. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts.
Hogan Lovells team for MorphoSys
Prof Dr Michael Schlitt (Partner, Frankfurt), Dr Sebastian Biller (Counsel, Munich) (both Lead, both Stock Corporation and Capital Markets);
Dr Michael Rose (Partner), Thomas Weber (Counsel), Dr Jonas Palme (Senior Associate), Dr Matthias Veicht (Associate) (all Corporate M&A, Munich);
Johanna Jungermann (Project Associate, Stock Corporation and Capital Markets, Frankfurt);
Mahvesh Qureshi (Partner), Leslie Reese (Partner), Joseph Gilligan (Partner), Brendan Oldham (Senior Associate) (all Corporate M&A, Washington D.C.);
Dr Jörg Schickert (Partner, Life Sciences, Munich);
Dr Thomas Freund (Partner, Banking & Loan Finance, Munich).
Inhouse Law (MorphoSys AG)
Charlotte Lohmann (Chief Legal & HR Officer, Member of the Executive Committee)
Virginie Pontlevoy (Vice President, Head of Legal Corporate & Business)